Shots:

• The approval is based on P-lll study which involves assessing Detectnet (copper Cu 64 dotatate injection) in Neuroendocrine Tumors (NETs) patients. Curium expects to launch detectnet immediately with doses available through various nuclear pharmacies
• The P-III results demonstrated that the clinical sensitivity and specificity provide great aid to clinicians to develop an accurate treatment approach for their NET patients. Additionally- 12.7-hrs. half-life allows detectnet to be produced centrally and shipped to sites
• Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients
  
    Ref: Globenewswire | Image: Radiomedix.com